{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RECURRENT+GLIOBLASTOMA", "query": { "condition": "RECURRENT GLIOBLASTOMA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 718, "total_pages": 72, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RECURRENT+GLIOBLASTOMA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T20:14:13.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02197169", "title": "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma or Gliosarcoma" ], "interventions": [ { "name": "Single intratumoral injection of DNX-2401", "type": "DRUG" }, { "name": "Interferon-gamma", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DNAtrix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-09-11", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-07-16", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 4, "location_summary": "Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197169" }, { "nct_id": "NCT04991870", "title": "Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Gliosarcoma", "Recurrent Supratentorial Glioblastoma", "Supratentorial Gliosarcoma" ], "interventions": [ { "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 25, "start_date": "2023-04-28", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991870" }, { "nct_id": "NCT01756729", "title": "Post-approval Study of NovoTTF-100A in Recurrent GBM Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "NovoTTF-100A", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NovoCure Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 13, "start_date": "2012-12", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2016-03-02", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01756729" }, { "nct_id": "NCT00504660", "title": "6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Glioma of Brain", "Glioblastoma Multiforme", "Brain Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib (Celebrex)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "6-Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2003-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2012-01-11", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504660" }, { "nct_id": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Regorafenib, (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Nivolumab (Opdivo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2021-02-03", "completion_date": "2024-03-29", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 6, "location_summary": "Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704154" }, { "nct_id": "NCT03973918", "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "BRAF V600E", "BRAF V600K", "Anaplastic Astrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Gliosarcoma", "Glioblastoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Research Bloods", "type": "BIOLOGICAL" }, { "name": "Tumor Tissue", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-07-29", "completion_date": "2023-10-01", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03973918" }, { "nct_id": "NCT00006773", "title": "Bortezomib in Treating Patients With Recurrent Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006773" }, { "nct_id": "NCT02323880", "title": "Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 59, "start_date": "2015-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323880" }, { "nct_id": "NCT01257594", "title": "EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "Cytoreductive Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Andrew B Lassman, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-01-07", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 4, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257594" }, { "nct_id": "NCT05917145", "title": "ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "WSD0628", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2024-01-17", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-07-22T20:14:13.737Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05917145" } ] }